首页> 外文期刊>International ophthalmology >Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy.
【24h】

Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy.

机译:晚期眼内视网膜母细胞瘤的交替动脉内和玻璃体内化疗:未经系统化疗的初步成功结果。

获取原文
获取原文并翻译 | 示例
           

摘要

To describe the efficacy of intravitreal chemotherapy (IViC) preceded by intra-arterial chemotherapy (IAC) for the treatment of advanced stage retinoblastoma. This non-comparative interventional case series retrospectively reviewed the medical records of six patients who presented within months of each other with unilateral retinoblastoma, Reese-Ellsworth stage Vb/D of ABC classification in the affected eye. After clinical and ophthalmoscopic evaluation, they underwent MRI to exclude local and CNS dissemination. The IAC was given to treat retinal masses and intravitreal injections to treat vitreous seeding. Patients had received two cycles (six infusions) of IAC, and from six up to ten melphalan injections into the vitreous, with an interval of 7-10 days between them. From one to four intravitreal injections were performed for partial remission or consolidation. No permanent complications of procedures have been reported. All patients underwent to bimonthly MRI examination, during treatment and every 3 months for 1 year after last injection, to exclude orbital dissemination. Successful control (100 %) of tumor masses and vitreous seeds was achieved in all cases at 12 months follow-up. Complications were posterior lens opacity, acute ischemic papillitis, partial CVR thrombosis, hypotonia (case 1), partial vitreous hemorrhage (case 4). No complications appeared in cases 2, 3, 5, and 6. No intraocular or orbital tumor recurrence or retinoblastoma metastases (follow-up range, 12-33 months) were observed. Sequential IAC and intravitreal melphalan for advanced retinoblastoma allowed to provide retinal and vitreous seed control.
机译:描述玻璃体内化学疗法(IViC)继之以动脉内化学疗法(IAC)治疗晚期视网膜母细胞瘤的疗效。该非比较性介入病例系列回顾性回顾了六个患病患者的病历,这些患者在几个月内出现单侧视网膜母细胞瘤,Reese-Ellsworth分期患眼的ABC分类为Vb / D。经过临床和检眼镜评估后,他们进行了MRI检查以排除局部和CNS传播。 IAC用于治疗视网膜肿块和玻璃体内注射以治疗玻璃体植入。患者接受了两次IAC周期(六次输注),从玻璃体注射六次至十次美法仑,两次间隔7至10天。进行1-4次玻璃体内注射以部分缓解或巩固。没有手术永久并发症的报道。所有患者在治疗期间以及最后一次注射后的1年中每3个月进行两次MRI检查,以排除眼眶扩散。随访12个月,所有病例均成功控制(100%)肿瘤块和玻璃体种子。并发症包括后晶状体混浊,急性缺血性乳头炎,部分CVR血栓形成,肌张力低下(病例1),部分玻璃体出血(病例4)。在第2、3、5和6例中未出现并发症。未观察到眼内或眼眶肿瘤复发或视网膜母细胞瘤转移(随访范围为12-33个月)。顺序IAC和玻璃体内美法仑治疗晚期视网膜母细胞瘤可提供视网膜和玻璃体种子控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号